0710 GMT - In Novartis's deal to buy Myricx Bio, the upfront payment relative to the potential milestones seems high, Vontobel analysts say in a note. Novartis will pay $1.1 billion upfront, with up to $400 million in potential additional payments, it said. The purchase is extraordinary to see, as Myricx Bio's platform technology hasn't reached late-stage clinical development, the Vontobel analysts say. However, it is difficult to judge with the information at hand, they add. The acquisition will bolster the Swiss pharma company's oncology offering, they say. (aimee.look@wsj.com)
(END) Dow Jones Newswires
July 06, 2026 03:10 ET (07:10 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments